#XBB.2.3

[ricisidro]

#DOH says the latest #COVID19 #Omicron #genomesequencing as of October 10-17, 2023 in Regions X (Northern Mindanao), XI (Davao), XII (SOCCSKSARGEN) and CAR showed XBB 2.3 Acrux was the most prevalent at 65% | via @iamguidodavid

#biosurveillance #Philippines

View this post on Instagram

A post shared by Jun Isidro (@rcisidro)

[covid-safer-hotties]

Reference saved in our archive

An excellent breakdown of the efficacy of covid vaccines in children with some haunting statistics included:

Finally, only 7.4% of children ages 5 to 17 years in our study had received an XBB vaccine by the end of April 2024, which is similar to California Department of Public Health estimates of 6% to 7% for this same age group and time period.

Even if we could actually vax our way out of the covid pandemic, there's nowhere near enough uptake to pretend like we can. Mask up. Clean the air. Take all the steps and precautions you can to help keep yourself and everyone around you safe and healthy.

Introduction Vaccine effectiveness of XBB messenger RNA COVID-19 vaccines against mild to severe outcomes has been shown for adults in multiple global settings.1-3 However, data describing the effectiveness of updated COVID-19 vaccines in children are scarce. We evaluated the BNT162b2 XBB vaccine (Pfizer-BioNTech) effectiveness in children ages 5 to 17 years during the 2023-2024 respiratory virus season in a large integrated US health system.

Methods Similar to prior studies,3 we conducted a test-negative case-control analysis to evaluate BNT162b2 XBB vaccine effectiveness against acute respiratory infection (ARI)-associated (eTable in Supplement 1) hospital admission and emergency department (ED) or urgent care visits among children ages 5 to 11 (using a 10-μg formulation) and 12 to 17 (30-μg formulation) years from October 10, 2023, through April 30, 2024, at Kaiser Permanente Southern California (KPSC). This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines. This study was approved by the KPSC institutional review board with a waiver of informed consent because it involved a minimal risk to study participants.

Cases had a positive SARS-CoV-2 polymerase chain reaction (PCR) or antigen test during a hospital admission or ED or urgent care visit, and controls tested negative and had no evidence of a positive SARS-CoV-2 test in the prior 90 days. In sensitivity analyses, we evaluated the impact of (1) restricting results to PCR testing only, and (2) excluding test-negative controls identified by antigen testing alone. Odds ratios (ORs) and 95% CIs comparing the odds of vaccination with 1 or more doses of BNT162b2 XBB with the odds of not being vaccinated with any XBB vaccine were calculated from multivariable logistic regression models (eMethods in Supplement 1). Vaccine effectiveness was calculated as 1 − OR multiplied by 100%. Significance was determined with 95% CIs.

Results Of 15 233 ARI encounters among children ages 5 to 17 years meeting eligibility criteria (7342 female [48.2%]; 1450 Asian or Pacific Islander [9.5%], 1358 Black [8.9%], 8752 Hispanic [57.5%], 2678 White [17.6%]), 9834 were among 5-to-11-year–olds (334 hospital admissions [3.4%], 4377 ED visits [44.5%], and 5123 urgent care visits [52.1%]) and 5399 were among 12-to-17-year–olds (125 hospital admissions [2.3%], 1953 ED visits [36.2%], and 3321 urgent care visits [61.5%]) (eFigure in Supplement 1). Overall, 336 of 9834 5-to-11-year–olds (3.4%) and 388 of 5399 12-to-17-year–olds (7.2%) tested SARS-CoV-2 positive (Table 1). In the full cohort, 1125 children (7.4%) received an XBB vaccine by the end of April 2024; 339 of 9834 5-to-11-year–olds (3.4%) and 264 of 5399 12-to-17-year–olds (4.9%) received BNT162b2 XBB vaccine with median time since vaccination of 75 days (range, 15-199 days) and 64.5 days (range, 16-197 days), respectively. Among those ages 5 to 11 and 12 to 17 years, estimated adjusted BNT162b2 XBB vaccine effectiveness was 68% (95% CI, 11%-88%) and 63% (95% CI, 20%-83%) against COVID-19–associated hospital admission or ED or urgent care visits, respectively, with an overall estimated vaccine effectiveness for all 5-to-17-year–olds of 65% (95% CI, 36%-81%) (Table 2). No COVID-19–associated hospitalizations occurred among those who received BNT162b2 XBB vaccine. Estimated vaccine effectiveness was generally similar for all age groups if results were restricted only to PCR test results or if antigen results were used only to identify cases (Table 2).

Discussion Our results suggest that the BNT162b2 XBB vaccine provided protection against COVID-19–associated hospitalization and ED or urgent care visits among children 5 to 17 years of age during the 2023-2024 season with estimated vaccine effectiveness point estimates ranging from 63% to 73%. The US rate of COVID-19–associated hospitalization was roughly 10.5 per 100 000 among 5-to-17-year–olds from October 2023 through April 2024.4 Assuming 65% vaccine effectiveness, vaccinating the roughly 54.3 million 5-to-17-year–olds in the US5 could have averted approximately 3700 hospitalizations and, using the approximately 30:1 ratio of hospitalizations to ED or urgent care visits we observed in our study, roughly 111 000 ED or urgent care visits during the 2023-2024 respiratory virus season. Our observational design has previously described limitations,3 including potential unmeasured confounding, potential misclassification of prior infection or whether ARI encounters were truly COVID-19–related, and lack of generalizability to other populations. Finally, only 7.4% of children ages 5 to 17 years in our study had received an XBB vaccine by the end of April 2024, which is similar to California Department of Public Health estimates of 6% to 7% for this same age group and time period.6 More efforts are needed to improve pediatric COVID-19 vaccine uptake.

[theculturedmarxist]

There have been many scandals associated with covid in the last nearly 4 years.

I want to tell you about another one that has got zero media coverage.

The top-line is this: the UK government gave more than 2.3 million vulnerable and older people a covid vaccine that isn’t matched to the currently dominant covid strains. And they did it to save money.

The dominant covid strains right now are known as the XBBs. They have been dominant since late summer in most places, when they took over from the BA strains of omicron.

But rather than give people the new more effective XBB vaccine, the British government decided to use up their stockpile of the older BA vaccines first.

The worst thing is, those who got the outdated vaccine were those first in line for vaccines, such as older people and people with health conditions.

But they won’t know this.

So 2.3 million vulnerable people in the UK are walking around thinking they are well-protected this winter against covid when they’re not.

The British government didn’t hide why it did this. On the official government webpage it spells it out. In bold are the clues hiding in plain sight.

“The choice of vaccine products for autumn 2023 has been determined based on available data on vaccine safety, effectiveness and immunogenicity, logistical factors, programmatic deliverability and a bespoke cost effective assessment. Other vaccines which may offer similar protection, but which would incur additional costs, are expected to be less cost effective within the bespoke cost-effectiveness assessment compared to pre-procured Omicron-variant mRNA COVID-19 vaccines.”

What they are saying, under the cover of the gross language of ‘bespoke cost effectiveness assessment,’ is that they’d already bought the older vaccines and it was cheaper to use them than buy extra new ones.

They used people’s bodies as asset dumps for old medical stock.

In the UK the booster roll-out began on September 11th. We know that in Scotland they switched over to XBB on September 25th and in England and Wales they switched to the new ones on October 2nd, as confirmed that day by Meaghan Kall, an epidemiologist at the UK’s health security agency responsible for covid.

But by September 29th the British government reported 2.35 million people had been covid boosted. So we know this was largely with the old vaccine (save 4 days in Scotland). In response to my thread on Twitter, many reported receiving the old vaccine. Even now, people are saying they’re still only being offered the old vaccine.

Boosting people with a vaccine not matched to the dominant strains will certainly lead to worse outcomes as an average than if these people had received the updated vaccine. People will die for this penny pinching.

But then the British government has for some time now been relaxed about killing people for austerity.

The Brits are also tightly restricting access to covid vaccines, in contrast to almost every other country. And in a final twist, the Brits are now stockpiling the new XBB vaccines and are almost certainly going to take the same approach to deploying an outdated vaccine next time round.

When I tweeted about this, the Guardian journalist George Monbiot responded and we subsequently exchanged emails. Monbiot did then write a very good column about the ongoing burden of covid in the UK and the various public health failures.

But the article omitted any mention of the millions who were given the older vaccine.

I can’t criticise Monbiot. I wouldn’t be surprised if he included this and it was cut by his editors. And his article stands head and shoulders above almost any other reporting of covid in the mass media, a mass media that has played a key part in normalising the transmission of a virus that has become the leading cause of infectious disease death in the world today.

These lies and misinformation about covid in the mass media continue. Last week was no exception.

The BBC’s health editor Nick Triggle wrote a truly noxious covid story full of half-truths, lies by omission and propaganda. He said covid was less deadly than the flu, that it is becoming a seasonal ‘bug’, that people who were concerned about rising hospitalisations were just anxious. (Nick Triggle’s sister-in-law is a Tory member of parliament, which might explain some things).

In the US, the New York Times interviewed the epidemiologist and long-time covid downplayer Michael Mina who said rates of long covid are drastically falling - without citing a shred of evidence - and said repeated exposure to covid for most people will not be harmful and will build immunity. In the comments below the piece, one person said the “excellent story begs the question as to whether healthy people should take any precautions against covid.” Job done.

Then there was the ‘long cold’ research paper which was amplified across global media.

If you missed it, the thrust was that long colds might be as common as long covid. So far, so fine.

But the findings were stripped of critical context in relation to covid.

It failed to acknowledge that even if long colds do exist, and almost certainly they do, Sars-Cov-2 is a different beast, behaving in a completely different way to other common cold-causing coronaviruses.

And rather than the conclusion here being ‘ok, so if long colds are this common, long covid might be very common too and maybe we should do something about it,’ the stories led us towards the conclusion that long covid itself is nothing to worry about because post-viral illness is nothing new.

All of this would have been bad enough without mentioning the methodology.

The study was conducted in 2020-2021 and relied on people self reporting a respiratory illness that they said wasn’t covid. We know for a fact that far fewer people got a respiratory illness that wasn’t covid in these years, so I expect a good number of these ‘not covids’ leading to ‘long colds’ were, in fact, covids leading to long covid. But again, the media stories failed to provide any of this context. Nick Triggle was one of those who wrote a story.

Triggled twice in two weeks.

Over and over, it seems that those who are concerned about covid come armed with data, and those who aren’t come armed with gut feeling in order to keep business-as-usual ticking over.

It’s 2019 again! Stop worrying!

Normalisation is the most powerful sociological force in the world today. Through a captured media, the ruling class can make us absorb a pandemic, accept climate collapse and shrug at apartheid. Change is unnecessary because nothing is wrong. It is just the natural order, flowing.

We also found out this week that just 2% of Americans have stepped up for the new covid jab, a rate of uptake that can be traced back to the early over-hyping of vaccines and the manufacturing of a narrative that says covid is mild and we’ve all achieved immunity now anyway.

I didn’t know where we’d be nearly four years on from the start of the pandemic, but I didn’t think we’d be here. New waves, millions being infected, thousands dying every week. And a media and public knowledge blackout of Novavax, the most effective vaccine. A vaccine we’ve known is the most effective for over two years.

It is tiring to keep up, to keep bearing witness to these fuck-ups, to this cruelty.

But we have to.

Because to believe in change means documenting the incompetence, the failure, the lies and the indifference that eventually compels that change to come.

[thoughtportal]

June 12 (Reuters) - COVID-19 vaccines being developed and manufactured for the 2023-2024 campaign should target one of the currently dominant XBB variants, the U.S. Food and Drug Administration's (FDA) staff reviewers said on Monday.

The comments were made in documents posted ahead of Thursday's meeting of a panel of FDA's independent experts, who are expected to make recommendations on what strain an updated COVID-19 booster should target.

An advisory group to the World Health Organization (WHO) in May recommended that COVID-19 booster shots for the year should be updated to target XBB subvariants.

Last year's COVID vaccine boosters in the United States featured both the original strain of the vaccine and Omicron in a so-called bivalent shot.

About 17% of people in the United States received a COVID booster shot in the 2022-2023 vaccination season, according to CDC data that was current through early May.

COVID-related deaths in the United States spiked in January, but have mostly fallen since then. They fell 14.3% in the past week.

Regulators say vaccines need to be updated to deal with the unpredictability of the virus.

"There is no indication that SARS-CoV-2 evolution is slowing down, though immunity appears to be mitigating severe clinical outcomes," the FDA's staff said.

The COVID vaccination campaign should feature a monovalent vaccine targeting either the XBB.1.5, XBB.1.16, or XBB.2.3, the FDA's reviewers said.

XBB subvariants accounted for more than 95% of the circulating virus variants in the United States by early June 2023, they added.

COVID-19 vaccine makers like Pfizer/BioNtech (PFE.N), Moderna Inc (MRNA.O) and Novavax Inc (NVAX.O) are already developing versions of their respective vaccines targeting XBB.1.5 and other currently circulating strains.

Reporting by Manas Mishra and Bhanvi Satija in Bengaluru and Michael Erman in New York; Editing by Anil D'Silva

[decentralvaccine]

Updated Covid 19 Vaccines Must Target The XBB Omicron Variant

U.S. Food and Drug Administration staff said updated Covid boosters should target XBB omicron subvariants for the upcoming fall and winter vaccination campaign.

The campaign should feature a monovalent vaccine targeting either XBB.1.5, XBB.1.16, or XBB.2.3, the staff said in a briefing document.

A panel of external advisors to the agency will meet Thursday to recommend a strain for new Covid-19 shots to target later this year.

Pfizer, Moderna and Novavax will be expected to update their jabs in time for the fall once that coronavirus strain is selected.

https://www.cnbc.com/amp/2023/06/12/new-covid-vaccines-in-fall-need-to-target-xbb-variant-fda-staff-says.html

[wregionalpe]

Covid-19: Minsa detectó nuevos linajes ómicron en el Perú

El Instituto Nacional de Salud (INS) reporta que los linajes ómicron XBB.1.16, XBB.1.9.1, XBB.1.9.2, y XBB.2.3, han sido detectados entre abril y mayo de este año en el Perú, informó el Ministerio de Salud (Minsa). Indicó que la primera es considerada una variante de interés por la Organización Mundial de la Salud (OMS), mientras que las otras son variantes bajo monitorización, y cuyas…

[aptitudpe]

Covid-19: Minsa detectó nuevos linajes ómicron en el Perú

El Instituto Nacional de Salud (INS) reporta que los linajes ómicron XBB.1.16, XBB.1.9.1, XBB.1.9.2, y XBB.2.3, han sido detectados entre abril y mayo de este año en el Perú, informó el Ministerio de Salud (Minsa). Indicó que la primera es considerada una variante de interés por la Organización Mundial de la Salud (OMS), mientras que las otras son variantes bajo monitorización, y cuyas…

[covid-safer-hotties]

Also preserved in our archive

By Mary Van Beusekom, MS

The adjusted effectiveness of the updated Pfizer/BioNTech COVID-19 XBB vaccine in the 2023-24 US respiratory virus season was 68% and 63% against hospitalization or emergency department (ED) or urgent-care visits among children aged 5 to 11 years and 12 to 17 years, respectively, with an overall effectiveness for both age-groups of 65%, a Kaiser Permanente Southern California (KPSC)-led research team estimates.

The investigators conducted a test-negative case-control analysis to assess vaccine effectiveness (VE) against COVID-related hospital admission and ED or urgent care visits among children aged 5 to 11 (using a 10-microgram [μg] formulation) and 12 to 17 years (30 μg) with acute respiratory infections (ARIs) from October through April 2024 at KPSC facilities. Case-patients had tested positive for COVID-19, and controls were uninfected.

Of 15,233 healthcare visits for ARI among children ages 5 to 17 years meeting eligibility criteria, 48.2% were girls, 9.5% were Asian or Pacific Islander, 8.9% were Black, 57.5% were Hispanic, and 17.6% were White.

The research findings were published today in JAMA Network Open.

"Vaccine effectiveness of XBB messenger RNA COVID-19 vaccines against mild to severe outcomes has been shown for adults in multiple global settings," the study authors wrote. "However, data describing the effectiveness of updated COVID-19 vaccines in children are scarce."

An estimated 111,000 ED, urgent care visits averted Of 15,233 ARI healthcare visits, 9,834 were among 5- to11-year-olds (334 hospital admissions [3.4%], 4,377 ED visits [44.5%], and 5,123 urgent care visits [52.1%]). Among 12- to 17-year-olds, there were 5,399 healthcare encounters (125 hospital admissions [2.3%], 1,953 ED visits [36.2%], and 3,321 urgent care visits [61.5%]).

A total of 336 of 9,834 5- to 11-year-olds (3.4%) and 388 of 5,399 12- to 17-year-olds (7.2%) tested positive for COVID-19. In the full cohort, 1,125 children (7.4%) received an XBB vaccine by study end; 339 of 9,834 5- to 11-year-olds (3.4%) and 264 of 5,399 12- to 17-year-olds (4.9%) received the vaccine. The median times since vaccination were 75 days and 64.5 days, respectively.

Estimated adjusted VE among participants aged 5 to 11 and 12 to 17 years was 68% (95% confidence interval [CI], 11% to 88%) and 63% (95% CI, 20% to 83%) against COVID-19 hospitalization or ED or urgent care visits, respectively, for an overall estimated VE for both age-groups of 65% (95% CI, 36% to 81%).

No COVID-19 hospitalizations occurred among vaccine recipients. VE was generally similar for all age-groups if results were restricted only to polymerase chain reaction (PCR) tests or if antigen test results were used only to identify cases.

The US COVID-19 hospitalization rate among 5- to 17-year-olds was about 10.5 per 100,000 during the study period. "Assuming 65% vaccine effectiveness, vaccinating the roughly 54.3 million 5-to-17-year–olds in the US could have averted approximately 3,700 hospitalizations and, using the approximately 30:1 ratio of hospitalizations to ED or urgent care visits we observed in our study, roughly 111,000 ED or urgent care visits during the 2023-2024 respiratory virus season," the researchers wrote.

They noted that a low proportion of participants had received the XBB vaccine by the end of the study period, similar to California Department of Public Health estimates of 6% to 7% for this age-group and period. "More efforts are needed to improve pediatric COVID-19 vaccine uptake," they concluded.

Study link: jamanetwork.com/journals/jamanetworkopen/fullarticle/2827807

[covid-safer-hotties]

also preserved on our archive

By Bill Shaw

There continues to be 1.1 million COVID-19 infections per day, according to the Pandemic Mitigation Collaborative (PMC)’s forecast model, which is based on the latest wastewater surveillance data from the US Centers for Disease Control and Prevention (CDC). The PMC model forecasts that SARS-CoV-2 transmission will continue at over 1 million infections per day for the next month. These levels are the highest for the months of August and September for the entire pandemic to date.

The PMC model has been updated with the latest report from version 2.0.0 to 2.0.1, with the major change being the elimination of the BioBot wastewater surveillance data. BioBot has not updated in over 3 weeks, nor has it explained why it is no longer reporting public data or whether and when it will resume doing so.

Other indicators tracked by the CDC are also at high levels. The percentage of positive COVID-19 tests is 16.7 percent, which far exceeds a best practice threshold of 5 percent. This is the highest test positivity rate in over a year, and it means that far too little testing is being done given the high levels of transmission.

Nevertheless, current CDC recommendations for testing do not urge or recommend individuals to get tested whatsoever, let alone if one is symptomatic or has been exposed. The CDC merely provides guidance for those who are self-motivated in getting tested.

Other indicators include that 2.3 percent of emergency department visits, 4.6 percent of hospitalizations, and 2.6 percent of deaths are due to COVID-19. The official emergency department, hospitalization and death rates—all known to be under-counts due to the dismantling of testing and pandemic surveillance—are higher than this time last year.

New viral variants that emerged this spring now make up an estimated 80 percent of all infections per CDC data. These variants evolved to escape existing immunity from prior infections and vaccinations, which is why transmission levels are so high at the current time. The predominant SARS-CoV-2 variant is the KP.3.1.1 variant, accounting for 42 percent of all infections.

Despite the rapid emergence and growth of the newer KP.2.3, KP.3, and KP.3.1.1 variants, the Food and Drug Administration (FDA) and vaccine manufacturers originally agreed to update vaccines to cover the rapidly fading JN.1 variant. However, the explosive growth of the newer variants caused FDA to change its mind and urge that vaccines cover the KP.2 strain.

Although the change in recommendation was not expected to delay availability of vaccines, the shortsightedness of planning for a “Fall vaccine campaign” is remarkable. COVID-19 has surged during every summer of the pandemic to date, and the new variants grew rapidly. The FDA did not approve the new KP.2-based vaccines from Pfizer and Moderna until August 23, which is concurrent with what the PMC model predicts will be either the highest or second highest transmission level of the summer.

However, as early as late April, researchers had identified that the KP.2 variant “…demonstrates significantly enhanced epidemiological fitness compared to its predecessors, including the dominant XBB lineage.” By early April 2024, KP.2 already made up 20 percent of infections in the UK.

This begs the question, why did vaccine manufacturers not have the new vaccines ready for the inevitable summer surge, and especially in light of the explosion of infections due to the new variants? The answer is rooted in the criminal “forever COVID” policy of the ruling class. Neither the FDA, nor the vaccine manufacturers, nor the politicians saw any urgency in protecting the public from the new strains.

Thus, the new vaccines, although certainly a welcome development, are too late for the tens of millions of individuals already infected this summer with the new variants. As noted by the September 9 PMC report: “The impact on potential Long COVID cases the next month will be staggering…”

After the FDA approval of August 23, CVS announced availability of the vaccine at its stores on August 28, and Walgreens announced availability beginning on September 6. Both dates are after the two peaks in daily COVID-19 transmission noted by PMC, August 10 and August 24.

Now that the vaccines are available, the CDC has updated its recommendations for vaccination, stating “Everyone ages 6 months and older should get a 2024–2025 COVID-19 vaccine.” This low level of urgency for vaccination is anemic even for CDC standards, compared to advisories it issued on the Health Alert Network urging COVID-19 vaccination.

Experts, including at the PMC, expect a winter wave that exceeds current transmission levels. The PMC model report notes: “Currently, we are expecting an extremely high ‘lull’ between the summer and winter waves the first week of November at around 850,000 daily infections.”

The messaging of politicians and the media, as summarized in a resolution adopted by the Socialist Equality Party at its Eighth Congress last month, has been that “COVID is over” and “will be with us forever.” This messaging has steadily eroded a sense of urgency on the part of the public and enabled vaccine misinformation to rise, with a net consequence that the vast majority of the population will forgo the protection offered by the new vaccines.

The silence and lack of urgency has persisted through the current summer wave of COVID-19. Indeed, the only mention Kamala Harris made to the pandemic in her debate with Donald Trump was to regurgitate the scientifically discredited Wuhan “lab leak” conspiracy theory.

Concurrently, authorities and the media fail to combat vaccine misinformation. KFF reported in July that a lawsuit filed by Kansas Attorney General Kris Kobach against Pfizer repeated numerous falsehoods about the vaccines. The filing of this lawsuit was followed by numerous social media posts echoing vaccine misinformation. The overwhelming media response was to report uncritically on the false allegations of the suit.

Last Fall, KFF conducted a survey showing that only 20 percent of eligible adults received last year’s COVID-19 vaccine within two months of its availability. Approximately half of respondents said they definitely or probably would not get the updated vaccine. KFF also found that previously vaccinated individuals who did not plan to get the vaccine cited a decreasing lack of personal concern about the virus.

Given the ongoing assault on public health, the numbers of eligible individuals who get the updated vaccine this fall are likely to drop further. When combined with new strains of the virus to which the population has less immunity, this is a recipe for increased death and disability due to COVID-19.

Every one of these developments is an indictment of the criminal “forever COVID” policies of the ruling class, which are bankrupt and completely antithetical to public health. The emergence of new strains is inevitable when the virus is enabled to spread widely. The delay in producing vaccines updated to the new strains is inexcusable, especially given the rapidity with which they emerged. The weakness of vaccine recommendations and the lack of testing recommendations, in the context of a high percentage positive test rate, fly in the face of public health best practices.

[ricisidro]

Based on the DOH's latest Covid-19 Biosurveillance Report on Dec. 8, a large majority of the samples sequenced from November 22 to December 1 remain XBB and its sublineages.

Out of the 36 samples sequenced, there were 34 samples that were classified as XBB.

These include 30 XBB.2.3 cases, 2 XBB.1.5 cases, and 1 case each of XBB.1.16 and XBB.1.9.1.

All the detected XBB subvariant cases were local cases from Western Visayas, Davao Region, and National Capital Region.

#DOH #Philippines #COVID19 #Omicron

#biosurveillance #genomesequencing #XBB

View this post on Instagram

A post shared by Jun Isidro (@rcisidro)

[ricisidro]

#DOH says the latest #COVID19 #Omicron #genomesequencing as of October 25, 2023 in Regions III (Central Luzon) and VI (Western Visayas) showed XBB 2.3 Acrux was the most prevalent at 79%. EG.5 was in 6% of samples | via @iamguidodavid

#biosurveillance #Philippines

View this post on Instagram

A post shared by Jun Isidro (@rcisidro)

[ricisidro]

#DOH says the latest #COVID19 #Omicron #genomesequencing as of October 9, 2023 in Regions XI (Davao) and XII (SOCCSKSARGEN) and BARMM showed XBB 2.3 Acrux was the most dominant at 55%. EG.5 had 3% of the samples | via @iamguidodavid

#biosurveillance #Philippines

View this post on Instagram

A post shared by Jun Isidro (@rcisidro)

[ricisidro]

#DOH says the latest #COVID19 #Omicron #genomesequencing on Sept 18 to Oct 3, 2023 in Regions VI (Western Visayas) and XI (Davao) showed 73% of cases were XBB types. The most dominant were XBB 2.3 Acrux and XBB 1.16 Arcturus with 7% each. One case of EG.5 was sampled. | via @iamguidodavid

#biosurveillance #Philippines

View this post on Instagram

A post shared by Jun Isidro (@rcisidro)

[ricisidro]

#DOH says the latest #COVID19 #Omicron #genomesequencing on September 11 to 12, 2023 showed 84% of cases were XBB types. The most dominant was XBB 2.3 Acrux with 39% followed by XBB 1.16 Arcturus with 22% and XBB 1.9.1 Hyperion at 14% | via @iamguidodavid

#biosurveillance #Philippines

View this post on Instagram

A post shared by Jun Isidro (@rcisidro)

[ricisidro]

#DOH says the latest #COVID19 #Omicron #genomesequencing on August 8 to September 4, 2023 shows 91% of cases were XBB types. The most dominant was XBB 2.3 Acrux with 39% followed by XBB 1.16 Arcturus with 22%. No BA 2.86 Pirola detected yet | via @iamguidodavid

#biosurveillance

View this post on Instagram

A post shared by Jun Isidro (@rcisidro)

[ricisidro]

View this post on Instagram

A post shared by Jun Isidro (@rcisidro)

#DOH says the latest #COVID19 #Omicron #genomesequencing on August 3 to 5, 2023 shows 93% of cases were XBB types. The most dominant was XBB 2.3 Acrux with 36% followed by XBB 1.16 Arcturus with 30% and XBB 1.91 Hyperion at 20%. No new EG.5 have been reported | via @iamguidodavid